Dr. Mattéa J. Finelli is an Assistant Professor in the Faculty of Medicine & Health Sciences at the University of Nottingham, UK. Dr. Finelli completed an MSc in Bioengineering from SupAgro and an MRes in Biomedical Research from Imperial College in 2007. She received her DPhil in Physiology, Anatomy, and Genetics (Neurosciences) from the University of Oxford in 2011. Dr. Finelli established her group in January 2020 at the University of Nottingham Biodiscovery Institute. Her group aims to advance our understanding of the molecular mechanisms underlying neurodegenerative diseases and to develop and test new therapeutic strategies for these disorders. More information can be found on the Finelli Lab website: https://mattea-finelli-lab.com
Dr. Peter L Oliver is a Visiting Associate Professor of Neuroscience at the University of Oxford (2018-). Peter completed a PhD at the MRC National Institute for Medical Research in 1999
where he studied the control of retroviral expression in the mouse genome. He
then joined Professor Kay Davies' group in the MRC Functional Genomics Unit,
Oxford, where he focused on studying gene function in the brain using mouse
models. This included models of neurodegeneration as well as human behavioural
disorders, such as schizophrenia. In 2013, he was awarded a European Research
Council Starting (Consolidator) Grant and established his independent group in
the Department of Physiology, Anatomy and Genetics, Oxford, to study a family of proteins (TLDc) that protect against oxidative stress in
neurons. In 2017, he became an MRC Programme Leader at the MRC Mammalian Genetics Unit at Harwell, UK, focussing on new mouse models of TLDc-associated disorders, including neurodegeneration and epilepsy. In 2022, he became Head of Biology at the MRC Nucleic Acid Therapy Accelerator, a translational academic Unit focussing on RNA therapeutics combining novel chemistry and biology approaches, see: www.natahub.org
